These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 11963637)

  • 1. [Efficacy-safety relationship of AT1 angiotensin II receptor antagonists: current data].
    Paoletti V; Di Veroli C; Pugliese M; Cammarella I; Cavina G; Turchetti P; Mammarella A
    Clin Ter; 2002; 153(1):61-4. PubMed ID: 11963637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antihypertensive advantages of angiotensin II AT1 receptor antagonism].
    Coca A; Giner V
    Rev Esp Cardiol; 1999; 52 Suppl 3():53-8. PubMed ID: 10614150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AT1-receptor blockers.
    Petkun W
    Eur Heart J; 2000 Feb; 21(4):335-7. PubMed ID: 10653684
    [No Abstract]   [Full Text] [Related]  

  • 4. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials.
    Stumpe KO
    Clin Ther; 2004; 26 Suppl A():A33-7. PubMed ID: 15291378
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Examining the association of olmesartan and other angiotensin receptor blockers with overall and cause-specific mortality.
    Lin JW; Chang CH; Caffrey JL; Wu LC; Lai MS
    Hypertension; 2014 May; 63(5):968-76. PubMed ID: 24516110
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Fast-acting sartan. High blood pressure therapy without long waiting time].
    MMW Fortschr Med; 2003 Jun; 145(24):55. PubMed ID: 12866306
    [No Abstract]   [Full Text] [Related]  

  • 7. Cardiology patient page. Angiotensin receptor blockers.
    Terra SG
    Circulation; 2003 Jun; 107(24):e215-6. PubMed ID: 12821593
    [No Abstract]   [Full Text] [Related]  

  • 8. The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.
    Elmfeldt D; Olofsson B; Meredith P
    Blood Press; 2002; 11(5):293-301. PubMed ID: 12458652
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Tendency and prospect of the development of new ARBs].
    Kim S
    Nihon Rinsho; 2002 Oct; 60(10):1881-6. PubMed ID: 12397678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II receptor antagonists in the treatment of hypertension.
    Kaplan NM
    Am Fam Physician; 1999 Sep; 60(4):1185-90. PubMed ID: 10507747
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of type 1 angiotensin II receptor blockers and angiotensin converting enzyme inhibitors in the treatment of hypertension.
    Weber MA
    J Hypertens Suppl; 1997 Dec; 15(6):S31-6. PubMed ID: 9493125
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Angiotensin receptor blockers -- finally the evidence is coming in: IDNT and RENAAL.
    Coats AJ
    Int J Cardiol; 2001 Jul; 79(2-3):99-102. PubMed ID: 11461726
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of angiotensin II antagonists in hypertension.
    Spence JD
    Can J Cardiol; 1999 Nov; 15 Suppl F():33F-5F. PubMed ID: 10579750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Dosage equivalents of AT1-receptor antagonists available in Germany].
    Dominiak P; Häuser W
    Dtsch Med Wochenschr; 2003 Oct; 128(44):2315-8. PubMed ID: 14593575
    [No Abstract]   [Full Text] [Related]  

  • 15. [Angiotensin receptor antagonist for therapy of patients with hypertension].
    Rakugi H; Ogihara T
    Nihon Rinsho; 1997 Aug; 55(8):2075-80. PubMed ID: 9284426
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Angiotensin I receptor antagonist losartan. Part II. Effects in arterial hypertension and diabetic nephropathy].
    Sidorenko BA; Preobrazhenskiĭ DV; Stetsenko TM; Tarykina EV; Tsurko VV
    Kardiologiia; 2003; 43(2):88-95. PubMed ID: 12891278
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [spACE, the last frontier? Renin inhibition in hypertension].
    Villa L
    G Ital Nefrol; 2008; 25(3):274. PubMed ID: 18473295
    [No Abstract]   [Full Text] [Related]  

  • 18. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS
    Blood Press Suppl; 2000; 1():19-22. PubMed ID: 11059631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Newly emerging pharmacologic differences in angiotensin II receptor blockers.
    Oparil S
    Am J Hypertens; 2000 Jan; 13(1 Pt 2):18S-24S. PubMed ID: 10678284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.